Dr. Gibson is Resident, Department of Family and Community Medicine, Department of Psychiatry and Behavioral Sciences, and Dr. McCarron is Associate Professor, Department of Anesthesiology, Division of Pain Medicine, Department of Psychiatry and Behavioral Sciences, Department of Internal Medicine, University of California, Davis School of Medicine, 4860 Y St, Ste 1600, Sacramento, CA 95617; E-mail: firstname.lastname@example.org.
All faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity.
The authors have disclosed that the U.S. Food and Drug Administration has not approved the use of gabapentin and cyclobenzaprine for the treatment of fibromyalgia; citalopram, paroxetine, and bupropion for the treatment of diabetic neuropathic pain; valproate for postherpetic neuralgia; lamotrigine for poststroke pain and HIV-related neuropathy; and amitriptyline and gabapentin for the treatment of complex regional pain syndrome as discussed in this article. Please consult the products' labeling for approved information.
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. This activity expires on December 31, 2014.